Lux Med Onkologia Sp. z o.o.
- Address
- lock Available on a paid plan
Breast Cancer Clinical Research
The oncology unit at Lux Med Onkologia conducts studies on HR+/HER2‑negative breast cancer, aiming to test novel endocrine‑based combinations and improve survival outcomes.
- Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2‑ Metastatic Breast Cancer Who Have Received Endocrine Therapy
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER‑4)
The trials emphasize response rates and adjuvant therapy effectiveness to reduce recurrence risk.
Renal Cell Carcinoma Trials
Researchers explore clear cell and non‑clear cell renal cell carcinoma to assess immunotherapy and targeted drug combinations for better disease control.
- An Open‑label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First‑line Treatment in Participants with Advanced clear cell renal cell carcinoma (ccRCC)
- Pembrolizumab + Lenvatinib for First Line Non‑Clear Cell, Renal Cell Carcinoma
The goal is to improve progression‑free survival and overall response in patients with advanced kidney cancer.
Bladder Cancer Investigation
The department evaluates peri‑operative immunotherapy for cis‑eligible muscle‑invasive bladder cancer, comparing pembrolizumab‑based regimens with standard chemotherapy.
- A global study to evaluate peri‑operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.
Primary endpoints include event‑free survival following radical cystectomy and lymph node dissection.
Metastatic Castration‑Resistant Prostate Cancer
Studies target metastatic castration‑resistant prostate cancer by testing novel checkpoint inhibitors combined with chemotherapy to extend radiographic progression‑free survival.
- A Study of Lorikerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration‑Resistant Prostate Cancer
The research aims to determine whether immune‑based therapy offers a benefit over standard docetaxel treatment.
MSI‑High Metastatic Colorectal Cancer
Trials focus on MSI‑High or dMMR stage IV colorectal cancer, assessing multi‑arm immunotherapy combinations to increase objective response rates.
- A Multi Arm Study in Participants with MSI‑High Metastatic Colorectal Cancer
The objective is to identify the most effective regimen among several investigational agents.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 58 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 57 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Incyte Corp.2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC8trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Lux Med Onkologia Sp. z o.o.
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 58 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 11 | Unknown | 2018-08-24 | 2026-07-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.